ILMN: 10-K Risk Factor Changes

2026 vs 2025  ·  SEC EDGAR  ·  2026-07-05
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

19
New Risks
30
Removed
88
Modified
83
Unchanged
🟢 New in Current Filing Severity10/10Det 10

Changes in tariffs, trade restrictions, and customs or export/import regulations have impacted, and we expect will continue to impact, our business by increasing costs and administrative burdens, disrupting cross-border flows, and affecting customer demand.

We operate a diversified, global supply chain. Recent tariff measures and related policy actions have already resulted in higher input costs and longer lead times, and we expect continued volatility in tariff rates, sector-specific duties, and licensing or other trade…

Read full text

We operate a diversified, global supply chain. Recent tariff measures and related policy actions have already resulted in higher input costs and longer lead times, and we expect continued volatility in tariff rates, sector-specific duties, and licensing or other trade requirements in the U.S. and key international markets (including China) that may further raise costs, constrain pricing, reduce demand, or cause inventory imbalances. While we pursue mitigation efforts, these actions may not be successful, timely, or economically feasible, and our ability to pass cost increases to customers may be limited, any of which could adversely affect our business, cash flows, financial condition, and results of operations.

🟢 New in Current Filing Critical Audit Matter 🔒
🟡 Modified Financial Overview 🔒
🟢 New in Current Filing Accounting Pronouncements Adopted in 2025 🔒
🟢 New in Current Filing Government Incentives 🔒
🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟢 New in Current Filing 4.750% Term Notes due 2030 (2030 Term Notes) 🔒
🟢 New in Current Filing Purchase Obligations 🔒
🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟢 New in Current Filing Indemnification Liability 🔒
🟢 New in Current Filing 8. GRAIL SPIN-OFF 🔒
🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟢 New in Current Filing 13. SUBSEQUENT EVENTS 🔒
🟢 New in Current Filing Contingent Consideration Liabilities 🔒
🟢 New in Current Filing 3.82% - 4.94% 🔒
🟢 New in Current Filing Employee Separation Costs 🔒
🟢 New in Current Filing State and local income taxes, net of federal income tax effect (1) 🔒
🔴 No Match in Current Filing 2022 Impairment of Goodwill 🔒
🔴 No Match in Current Filing 0% Convertible Senior Notes due 2023 (2023 Convertible Notes) 🔒
🔴 No Match in Current Filing DOJ Civil Investigative Demand 🔒
🔴 No Match in Current Filing Supplemental Information 🔒
🟡 Modified Use of Estimates 🔒
🔴 No Match in Current Filing In April 2024, the FDA issued the Final Rule relating to Laboratory Development Tests (LDTs). Newly developed LDT products may be subject to regulatory clearance or approval, and could result in adverse impacts to our business, financial condition, or results of operations. 🔒
🔴 No Match in Current Filing Critical Audit Matters 🔒
🔴 No Match in Current Filing GRAIL Contingent Consideration 🔒
🔴 No Match in Current Filing Impairment assessment of GRAIL in-process research and development (IPR&D) 🔒
🔴 No Match in Current Filing Accounting Pronouncements Adopted in 2022 🔒
🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🔴 No Match in Current Filing 2024 Impairment of Goodwill 🔒
🔴 No Match in Current Filing 2023 Impairment of Goodwill 🔒
🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🔴 No Match in Current Filing Liability-Classified RSU 🔒
🔴 No Match in Current Filing Other Liability-Classified Awards 🔒
🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🔴 No Match in Current Filing Acquisition of GRAIL 🔒
🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🔴 No Match in Current Filing Shareholder Derivative Complaints 🔒
🔴 No Match in Current Filing Books and Records Action 🔒
🔴 No Match in Current Filing BGI Genomics Co. Ltd. and its Affiliates 🔒
🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🔴 No Match in Current Filing POWER OF ATTORNEY 🔒
🟡 Modified Disruption of critical information technology systems could have an adverse effect on our operations, business, customer relations, and financial condition. 🔒
🟡 Modified The markets we serve are dynamic — we face intense and increasing competition, which could render our products obsolete, result in significant price reductions, or substantially limit the volume of products that we sell, and increasing customer concentration makes us more dependent on key customers. 🔒
🟡 Modified Revolving Credit Agreement 🔒
🟡 Modified Gross Margin 🔒
🟡 Modified the Program 🔒
🟡 Modified RESULTS OF OPERATIONS 🔒
🟡 Modified Share-Based Compensation 🔒
🔴 No Match in Current Filing The Spin-Off could adversely affect the market value of the CVRs. 🔒
🔴 No Match in Current Filing (Accumulated 🔒
🔴 No Match in Current Filing 5. GOODWILL, INTANGIBLE ASSETS, AND ACQUISITIONSGoodwill 🔒
🔴 No Match in Current Filing 4.35% - 5.54% 🔒
🔴 No Match in Current Filing SEC Inquiry Letter 🔒
🟡 Modified Our products, if used for the diagnosis of disease, could be subject to government regulation, and the regulatory approval and maintenance process for such products may be expensive, time-consuming, and uncertain both in timing and in outcome. Since our strategy includes an emphasis on increasing our participation in clinical markets, we will be increasingly exposed to these risks. 🔒
🟡 Modified If we do not successfully manage the development, manufacturing, and launch of new products or services, including product updates and transitions, our financial results could be adversely affected. 🔒
🟡 Modified ADOPTIONS, MODIFICATIONS OR TERMINATIONS OF TRADING PLANS 🔒
🟡 Modified Share Repurchases 🔒
🟡 Modified Provision for Income Taxes 🔒
🟡 Modified Armed conflict in Ukraine, Russia, the Middle East or elsewhere could also negatively impact us. 🔒
🟡 Modified Regulatory authorities in China have added Illumina to the List of Unreliable Entities, which could result in fines or restrictions on our ability to do business in China and could have a material adverse effect on our revenue and results of operations. 🔒
🟡 Modified Restricted Stock 🔒
🟡 Modified Employee Stock Purchase Plan 🔒
🟡 Modified Shareholder Derivative Complaints 🔒
🟡 Modified 12. SEGMENT AND GEOGRAPHIC INFORMATIONReportable Segment Information 🔒
🟡 Modified Share-Based Compensation 🔒
🟡 Modified Accounting Pronouncements Pending Adoption 🔒
🟡 Modified 6. STOCKHOLDERS' EQUITY 🔒
🟡 Modified the Program 🔒
🟡 Modified Derivative Financial Instruments 🔒
🟡 Modified 7. SUPPLEMENTAL BALANCE SHEET DETAILSAccounts Receivable 🔒
🟡 Modified Revenue by Geographic Area 🔒
🟡 Modified Liability-Classified Awards 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified Operating Expense 🔒
🟡 Modified (In millions, except per share amounts) 🔒
🟡 Modified Other Income (Expense) 🔒
🟡 Modified 4. INTANGIBLE ASSETS, GOODWILL AND ACQUISITIONS Intangible Assets 🔒
🟡 Modified (In millions) 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified Securities Class Actions 🔒
🟡 Modified Restructuring 🔒
🟡 Modified CONTROLS AND PROCEDURES 🔒
🟡 Modified About Illumina 🔒
🟡 Modified Fiscal Year 🔒
🟡 Modified Revenue Recognition 🔒
🟡 Modified Stock Units 🔒
🟡 Modified Financial Statement Schedules 🔒
🟡 Modified (In millions) 🔒
🟡 Modified Deferred Compensation Plan 🔒
🟡 Modified 2024 Impairment of Goodwill 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified LIQUIDITY AND CAPITAL RESOURCES 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified Remaining Performance Obligations 🔒
🟡 Modified 9. LEGAL PROCEEDINGS 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified (In millions, except par value) 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified Fair Value Measurements 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified Venture Funds 🔒
🟡 Modified (Accumulated 🔒
🟡 Modified Marketable Equity Securities 🔒
🟡 Modified MARKET INFORMATION 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified Purchases of Equity Securities by the Issuer 🔒
🟡 Modified 10. INCOME TAXES 🔒
🟡 Modified CONSOLIDATED FINANCIAL STATEMENTS 🔒
🟡 Modified Geographic Data 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified Accrued Liabilities 🔒
🟡 Modified Property and Equipment 🔒
🟡 Modified Revenue by Source 🔒
🟡 Modified Retirement Plan 🔒
🟡 Modified 5. DEBT AND OTHER COMMITMENTSSummary of Term Debt Obligations 🔒
🟡 Modified Advertising Costs 🔒
🟡 Modified Opinion on the Financial Statements 🔒
🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒
🟡 Modified Nasdaq Biotechnology Index, and S&P 500 Index 🔒
🟡 Modified Following the Spin-Off, we remain the obligor on the contingent value rights (the CVRs) we issued in connection with the GRAIL Acquisition, and the Spin-Off could adversely affect the market value of the CVRs. 🔒
🟡 Modified Cash Flow Summary 🔒
🟡 Modified Earnings (Loss) per Share 🔒
🟡 Modified 5.800% Term Notes due 2025 (2025 Term Notes) and 5.750% Term Notes due 2027 (2027 Term Notes) 🔒
🟡 Modified RECENT ACCOUNTING PRONOUNCEMENTS 🔒
🟡 Modified Sales of Unregistered Securities 🔒
🟡 Modified Performance Stock Options (1) 🔒
🟡 Modified Income Taxes 🔒
🟡 Modified Contract Assets and Liabilities 🔒
🟡 Modified 2.550% Term Notes due 2031 (2031 Term Notes) 🔒
136 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →